hotspot -WSS

hotspot

author：leisure time 2025-08-12 09:12:01 - browse：214

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： How are insurers handling Leqembi and related scans?

WSS

Women's World Cup brings attention to abuse in soccer

One Duchenne patient's bittersweet hope for new treatment

Biotech lab space demand falls sharply

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Lasker Awards 2023: Winners in biomedical research

knowledge

hotspot

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Biotech lab space demand falls sharply

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

EpiPen alternative approval delay highlights citizen petition issue

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Senators: Long

Medicare proposal to cover medical devices draws a mixed reaction

STAT Virtual Event: Putting AI to the Test

The high cost of giving birth even with insurance

Why are Kaiser Permanente staff considering a strike?

hotspot

Drug for rare kidney disease narrowly misses mark in clinical trial

France's anti

The debate over Covid

CDC's new outbreak response network to include Northeastern

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

What Congress can do to address the rural doctor shortage

focus

leisure time

leisure time

hotspot